drivers in HTAs today (scale 1, low to 5, high) were clinical trial design (mean 4.45), right endpoints (mean 4.40), and size …‑relevant endpoints; and a transparent and consistent management of both HTA and regulatory procedures as well as their interface …

towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease … and endpoint selection, were identifed. At the inaugural convention of the European Access Academy dedicated working … fragmented treatment landscape, ii) reasonable number of comparators in PICOs, iii) shape Early Advice so that comparator fulfls …

towards the choice of adequate comparator(s), selection of endpoints that are relevant to patients with a given disease … and endpoint selection, were identifed. At the inaugural convention of the European Access Academy dedicated working … fragmented treatment landscape, ii) reasonable number of comparators in PICOs, iii) shape Early Advice so that comparator fulfls …

The full-text of this article is not currently available in ORA, but you may be able to access the article via the … publisher copy link on this record page. Citation: Bayne, T. & Pacherie, E. (2007). 'Narrators and comparators: the architecture …

unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints … endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also … clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly …

unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints … endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also … clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly …